Beaumont Financial Advisors’s TherapeuticsMD TXMD Stock Holding History

Beaumont Financial Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-200	Closed	-$7K	–	373
2021 Q3	$7K	Hold	200	–	–	﹤0.01%	354
2021 Q2	$12K	Sell	200 -500	-71%	-$30.3K	﹤0.01%	365
2021 Q1	$47K	Hold	700	–	–	﹤0.01%	334
2020 Q4	$42K	Hold	700	–	–	﹤0.01%	328
2020 Q3	$55K	Hold	700	–	–	0.01%	304
2020 Q2	$44K	Hold	700	–	–	﹤0.01%	275
2020 Q1	$37K	Hold	700	–	–	﹤0.01%	232
2019 Q4	$85K	Hold	700	–	–	0.01%	277
2019 Q3	$127K	Hold	700	–	–	0.01%	265
2019 Q2	$91K	Hold	700	–	–	0.01%	244
2019 Q1	$170K	Buy	700 +114	+19%	+$30.2K	0.02%	224
2018 Q4	$112K	Hold	586	–	–	0.02%	191
2018 Q3	$192K	Hold	586	–	–	0.02%	223
2018 Q2	$183K	Buy	586 +80	+16%	+$24.4K	0.02%	199
2018 Q1	$123K	Buy	+506	New	+$142K	0.01%	200

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Beaumont Financial Advisors's TXMD Position: Q4 2021 in Review

Beaumont Financial Advisors sold out of TherapeuticsMD (TXMD) in Q4 2021, closing a stake of 200 shares — an estimated $7K sold.

Beaumont Financial Advisors first reported a position in TXMD in Q1 2018 and held it in 15 quarters. The position peaked at $192K in Q3 2018. 131 funds tracked by Wall St. Rank hold TXMD as of Q4 2021.

Beaumont Financial Advisors reported no remaining TherapeuticsMD position as of Q4 2021 after selling out during the quarter.
Beaumont Financial Advisors sold 200 TherapeuticsMD shares in Q4 2021, an estimated $7K.
Beaumont Financial Advisors first reported a position in TherapeuticsMD in Q1 2018 and held it in 15 quarters.
Beaumont Financial Advisors's TherapeuticsMD position peaked at $192K in Q3 2018.
131 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2021.

Based on Beaumont Financial Advisors's 13F filing for Q4 2021, filed 7 Feb 2022.